Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,807
  • Shares Outstanding, K 22,428
  • Annual Sales, $ 77,350 K
  • Annual Income, $ -79,720 K
  • 60-Month Beta -0.50
  • Price/Sales 3.53
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate 0.13
  • Low Estimate -0.48
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +79.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.73 +17.33%
on 10/02/19
13.47 -6.53%
on 10/22/19
+0.75 (+6.33%)
since 09/20/19
3-Month
9.10 +38.35%
on 08/05/19
13.47 -6.53%
on 10/22/19
+2.67 (+26.92%)
since 07/22/19
52-Week
5.53 +127.66%
on 03/25/19
13.47 -6.53%
on 10/22/19
+5.37 (+74.38%)
since 10/22/18

Most Recent Stories

More News
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 98.12 (+0.87%)
GNCA : 2.61 (+0.38%)
REPH : 12.59 (-3.89%)
ZTS : 122.81 (-2.88%)
CPRX : 5.49 (+0.73%)
FLXN : 14.73 (-1.70%)
VRCA : 13.97 (-7.30%)
Will Recro Pharma Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Recro Pharma.

REPH : 12.59 (-3.89%)
Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates

Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

REPH : 12.59 (-3.89%)
Recro Pharma: 2Q Earnings Snapshot

MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $2.8 million in its second quarter.

REPH : 12.59 (-3.89%)
Recro Pharma Reports Second Quarter 2019 Financial Results

Record Results and Raising Guidance

REPH : 12.59 (-3.89%)
Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019

Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that...

REPH : 12.59 (-3.89%)
Recro Pharma to Present at Upcoming Investor Conferences

Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that Gerri...

REPH : 12.59 (-3.89%)
Pape Diop propose des formes de financements innovants

"Les communes et autres collectivités locales doivent réfléchir sur les modalités d'augmenter leur budget en recourant à des financements innovants", a dit samedi à Louga, Pape Diop.

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

BSTC : 47.23 (-0.53%)
CPRX : 5.49 (+0.73%)
REPH : 12.59 (-3.89%)
ESALY : 68.0000 (+32.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade REPH with:

Business Summary

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough...

See More

Key Turning Points

2nd Resistance Point 13.82
1st Resistance Point 13.21
Last Price 12.59
1st Support Level 12.24
2nd Support Level 11.88

See More

52-Week High 13.47
Last Price 12.59
Fibonacci 61.8% 10.44
Fibonacci 50% 9.50
Fibonacci 38.2% 8.56
52-Week Low 5.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar